Competitor Analysis: Antibody-Drug Conjugates -





 

The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated with a drug payload for treatment of cancer as of December 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. 

The report includes a compilation of current active projects in research and development of antibody-drug conjugates and other immunoconjugates in oncology. In addition, the report lists company-specific R&D pipelines of antibody-drug conjugates. Competitor projects are listed in a tabular format providing information on: 

•Drug Codes,
•Target / Mechanism of Action,
•Class of Compound,
•Company,
•Product Category,
•Indication,
•R&D Stage and
•additional comments with a hyperlink leading to the source of information.
 

Index
•Antibody-Drug Conjugates (ADC)
•Other Immunoconjugates in Oncology
•Corporate Antibody-Drug Conjugate R&D Pipelines
•About La Merie
 

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
 

  

 

 

 •Antibody-Drug Conjugates (ADC)
•Other Immunoconjugates in Oncology
•Corporate Antibody-Drug Conjugate R&D Pipelines
•About La Merie